John G. Cox
Chief Executive Officer
Mr. Cox is Chief Executive Officer of Torque. He previously was CEO of Bioverativ, leading its spin-out from Biogen in 2016 through its acquisition by Sanofi in 2018. Prior to that, he held several senior executive positions at Biogen from 2003 to 2016, most recently serving as Executive Vice President of Pharmaceutical Operations and Technology, with responsibility for overseeing Biogen’s global manufacturing facilities, supply chain operations, technical development, quality and engineering, and development and commercialization of Biogen’s biosimilars business. From October 2015 to May 2016, Mr. Cox also served as interim Executive Vice President, Global Therapeutic Operations, responsible for Biogen’s therapeutic groups of Specialty Medicines and Rare Diseases, which included responsibility for the global commercial performance of Biogen’s marketed products. His additional positions with Biogen included Senior Vice President of Technical Operations, Senior Vice President of Global Manufacturing, and Vice President of Manufacturing and General Manager of Biogen’s operations in Research Triangle Park, North Carolina. Mr. Cox received a BS in Cell Biology from California State University and an MBA in Finance from the University of Michigan.

Thomas Lars Andresen, PhD
Chief Scientific Officer and Co-Founder
Dr. Andresen is Chief Scientific Officer and a co-founder at Torque. Prior to joining Torque, he held positions at the prestigious Technology University of Denmark (DTU), including Professor and Head of Department at DTU Nanotech and Head of the DTU Center for Nanomedicine and Theranostics. Dr. Andresen has founded several cancer medical technology and biotechnology companies in Europe focused on chemotherapy and radiation therapy and has pioneered multiple technologies that are in ongoing clinical trials. Dr. Andresen has more than 20 years of research and development experience in the fields of organic chemistry, biophysics, advanced materials engineering, and cancer biology and is an author on more than 100 research or review articles and multiple patent applications.

Becker Hewes, MD
Chief Medical Officer
Dr. Hewes is Chief Medical Officer of Torque. He has more than 10 years of industry experience, most recently serving as an Executive Medical Director at Novartis Institute for Biomedical Research, where he was responsible for a wide array of clinical and preclinical immuno-oncology compounds as well as the early clinical development of ribociclib in breast cancer. Dr. Hewes has held positions within early oncology clinical development at both Genzyme and AstraZeneca. At Wyeth Oncology, he was responsible for the supplemental NDA filing for Torisel in Mantle Cell Lymphoma as well as the phase 1-3 program for bosutinib that resulted in FDA approval in chronic myeloid leukemia. Prior to joining industry, Dr. Hewes’ research focused on preclinical models of anti-tumor immunity at the Emory-Yerkes Vaccine Center.

Sok Cheng Soh, MBA
Chief Financial Officer
Ms. Soh is Chief Financial Officer of Torque. She brings more than 25 years of experience in finance and public accounting to her position as Chief Financial Officer of Torque, including treasury, controllership, operations, and financial planning. Prior to joining Torque, Ms. Soh was Vice President, Treasury and Tax at Bioverativ, a biotechnology company acquired in 2018 by Sanofi, where she established and built the company’s tax and treasury capabilities. Previously, she was Assistant Treasurer at Boston Scientific, where she led capital market initiatives, financial risk management, and treasury operations. She holds an MBA from the University of Chicago Booth School of Business and a Bachelor of Accounting from the University of Singapore.

Jennifer Camacho, JD
Chief Legal Officer
Ms. Camacho is the Chief Legal Officer at Torque. Previously, she was the Chief Legal Officer for Gen9 until its acquisition by Ginkgo Bioworks in January 2017. She is a member of the Patent Public Advisory Committee to the U.S. Patent and Trademark Office, appointed by the U.S. Secretary of Commerce in 2015. Prior to joining Gen9, Ms. Camacho was a partner in Greenberg Traurig, LLP, and Proskauer Rose, LLP. She holds a JD from Boston College Law School.

Back to Top